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Respiratory bronchiolitis-associated interstitial lung disease (RB-ILD) is a rare, mild inflammatory pulmonary disorder
that occurs almost exclusively in current or former heavy smokers, usually between the third and sixth decades,
most likely with no gender predilection. The onset is usually insidious with exertional dyspnea and persistent cough,
which may be non-productive, developing over a course of weeks or months. RB-ILD may also be diagnosed in
asymptomatic patients with functional impairment and chest radiograph or high-resolution computed tomography
(HRCT) abnormalities. Histologically, RB-ILD is characterized by the accumulation of yellow-brown pigmented
macrophages within the lumens of respiratory bronchioles and alveolar ducts, associated with a patchy submucosal
and peribronchiolar chronic inflammation. Common findings also include mild bronchiolar and peribronchiolar alveolar
fibrosis that expands contiguous alveolar septa and leads to architectural distortion as well as centrilobular emphysema.
Chest radiographs in patients with RB-ILD typically show fine reticulonodular interstitial opacities, while on HRCT central
and peripheral bronchial wall thickening, centrilobular nodules, and ground-glass opacities associated with upper lobe
centrilobular emphysema are most frequently reported. Pulmonary function testing may be normal but usually
demonstrates mixed, predominantly obstructive abnormalities, often combined with hyperinflation and usually
associated with a mild to moderate reduction in carbon monoxide diffusion capacity (DLco). The course of RB-ILD is
heterogeneous. Some patients respond favorably to corticosteroids and/or smoking cessation, but often there is no
functional improvement and the disease progresses despite smoking cessation and treatment.
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Respiratory bronchiolitis-associated interstitial lung disease
(RB-ILD, ORPHA79127).
The disease has not been referred to by any other
synonym in medical literature.Definition
Respiratory bronchiolitis-associated interstitial lung disease
(RB-ILD) is a rare, mild inflammatory pulmonary disorder
that occurs almost exclusively in current or former heavy
smokers, usually between the third and sixth decades, most
likely with no gender predilection. It is characterized by
shortness of breath and cough, pulmonary function abnor-
malities of obstructive, restrictive, or mixed pattern, and
high resolution computed tomography (HRCT) scans
showing centrilobular micronodules, ground-glass opaci-
ties, and peribronchiolar thickening, often accompanied by
tobacco-related centrilobular emphysema [1,2].* Correspondence: asieminska@gumed.edu.pl
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made available in this article, unless otherwiseRB-ILD is a combined respiratory bronchiolitis (RB)
and interstitial lung disease (ILD). The first component
of the disease - RB - was first described in 1974 as an in-
cidental histologic lesion in the lungs of young asymp-
tomatic cigarette smokers who died from nonpulmonary
causes [3]. These pathological changes included accumula-
tion of pigmented macrophages within the bronchioles and
the peribronchiolar alveolar spaces in association with min-
imal chronic inflammation in the bronchiolar walls and the
neighboring interstitium, and were rarely found in non-
smokers [3]. Since that initial report, RB has been recog-
nized as an extremely common histological lesion thought
to occur in virtually all cigarette smokers, and the term re-
fers to the universal inflammatory reaction in respiratory
bronchioles, known as a smoker’s bronchiolitis [4-6].
Subsequently, in 1987, Myers et al. described six patients’
smoking histories that had an extent of alveolar accumula-
tion of pigmented macrophages and mural inflammation
on surgical biopsy specimens that was severe enough to
produce clinical, physiologic, and imaging features of ILD
[6]. This clinicopathological entity was termed “respiratoryMed Central Ltd.; licensee BioMed Central Ltd. This is an Open Access article
mmons Attribution License (http://creativecommons.org/licenses/by/4.0), which
roduction in any medium, provided the original work is properly credited. The
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data
stated.
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Contrary to RB alone, RB-ILD is an uncommon disorder
found in a far smaller proportion of smokers [4,6]. Some
authors have regarded RB-ILD as an exaggerated RB with
more extensive peribronchiolar interstitial fibrosis [7-9],
while others [4,6] have considered the histologic features of
RB and RB-ILD indistinguishable and have separated the
two based on the presence of clinical evidence of ILD.
RB-ILD has been incorporated into the broad category
of diffuse parenchymal lung diseases that are also known
as the interstitial lung diseases (ILDs). Within this large
heterogeneous group of diseases, mostly of unknown eti-
ology, RB-ILD belongs to a subgroup termed idiopathic
interstitial pneumonias (IIPs) [1,10]. The classification of
IIPs was first standardized in 2002 by American Thoracic
Society (ATS) and European Respiratory Society (ERS)
consensus that combined the histopathologic pattern of
IIPs seen on lung biopsy with clinical findings in order to
establish a final clinicopathologic diagnosis [1,11]. Accord-
ing to a recent update, the ATS/ERS classification of IIPs
has abstracted a group of six major IIPs, including RB-
ILD, from rare IIPs and unclassifiable IIPs [10].
Most insight into RB-ILD to date has been provided
by five case series [6-8,12,13] totaling 78 patients with
biopsy-proven RB-ILD, These studies have provided de-
scriptions of clinical and physiological features, pathological
and radiographic/HRCT appearances, and outcomes of the
disease. Additionally, there have been several other reports
focused mainly on the differential diagnosis of RB-ILD
based on radiological findings [9] and their correlation with
clinical and physiological findings [14], or on follow-up
after smoking cessation [14,15].
In spite of the substantial clinical heterogeneity of these
studies, it has been consistently reported that patients with
RB-ILD are usually ever cigarette smokers with at least 30
pack-years at the time of diagnosis [6-9,12,13]. Only inci-
dental single cases of RB-ILD in non-smokers have been
reported, including patients exposed to second-hand
smoke [8,16]. The age at symptom onset ranges from 22
to 70 years, with median values of 36–54 years [6-8,12,13].
When the disease occurred at a younger age, it was usually
in heavy smokers who had smoked 2 to 3 packs of ciga-
rettes for at least 10 years. However, the issue of gender
predilection remains unclear. Some reports have indicated
that men were more often affected than women [6,9,12],
while others have reported contradictory data [13] or no
gender predilection [8]. Therefore, the viewpoint that
there is no gender predilection seems most likely to be
accurate [2].
Epidemiology
The prevalence and incidence of RB-ILD is unknown and
has remained difficult to assess for many years. Available
epidemiological data on RB-ILD are sparse, and eventuallyrepresent a calculation of relative frequency of RB-ILD
among ILDs, or more specifically, among IIP cases.
In several earlier case series, the incidence of RB-ILD was
usually estimated together with that of desquamative inter-
stitial pneumonia (DIP), and these two IIPs were found to
account for 10%–17% of the study samples [17-20]. RB-ILD
was recorded separately in only two of these case series,
and accounted for 2% and 13% of cases [17,20].
Several more recent studies have provided additional data
on the epidemiology of ILDs under the current ATS/ERS
consensus on the classification of IIPs and have even calcu-
lated the relative frequency of RB-ILD among them
[21-25]. A wide epidemiological study conducted in Greece
found that the prevalence and incidence of RB-ILD were
0.07 per 100,000 and 0.04 per 100,000 [23], respectively.
In contrast, in the Saudi Arabian register of newly diag-
nosed ILD cases, RB-ILD cases accounted for 5.5% of all
types of IIPs [24]. A German pathology review of ILD cases
revealed 9.5% of RB-ILD cases among all types of IIPs [25].
Clinical description
History and physical
The onset of RB-ILD is usually insidious with exertional
dyspnea, symptomatic wheezing, and persistent cough,
which may be non-productive, developing over a course
of weeks or months [6-8,13]. This clinical picture can be
masked by concomitant smoking-related chronic bron-
chitis. RB-ILD may also be diagnosed in asymptomatic pa-
tients with functional impairment and chest radiograph or
HRCT abnormalities. In most cases, RB-ILD is not a dis-
abling disease and patients display only mild symptoms.
However, some patients may have significant dyspnea and
hypoxemia because of more extensive ILD [1]. Chest pain
and weight loss were less frequent and hemoptysis and
fever were reported incidentally [8], and might have re-
sulted from underlying disease including lower respiratory
tract infection [26]. In the literature, there is only one case
of an acute presentation of RB-ILD with fevers and sweats
as general symptoms, and increasing breathlessness and
non-productive cough as respiratory symptoms [27].
On physical examination, although not universal, bibasi-
lar end-inspiratory crackles are the most common signs. A
case series report by Portnoy et al. [13], that included a
sample size that was twice that of the next largest sample
and represented the single largest experience reported to
date, showed wheezing as a common sign in 69% of RB-
ILD cases, significantly more frequent than in prior re-
ports [4,7,8].
Digital clubbing was either not reported at all [6,7] or
was an uncommon sign with an incidence not exceeding
25% [8,12,13]. A single reported case of digital clubbing in
RB-ILD probably caused by lung cancer that was detected
at follow up [28] might warrant that occurrence of clubbing
in an RB-ILD patient with a typical average of a 30–40-year
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occult tumor [6].
Physiologic changes
Pulmonary function tests in patients with minimal symp-
toms usually reveal a mild to moderate decrease in DLco.
In patients with more severe symptoms, both airway ob-
struction and restriction or occasionally an isolated increase
in residual volume may be found [6]. These features result
from the variable extent of both RB-ILD and centrilobular
emphysema in different cases. Patients with more advanced
clinical manifestations of disease may have more significant
reductions in carbon monoxide transfer [29].
The large case series reported by Portnoy et al. showed
that an obstructive pattern was the most common pulmon-
ary function defect (47%), while pure restriction or mixed
defects were less common (31% and 9%, respectively), and
that 13% of patients had normal spirometry data [13]. The
authors of this study did not support the common reduc-
tion in DLco in patients with RB-ILD. Normal initial DLco
values were demonstrated in 36% of patients, suggesting
lower sensitivity of that marker of clinically significant dis-
ease than had been previously indicated [6-8,12].
Natural history and prognosis
Definitive reports of natural history of RB-ILD are not
available due to the relatively small number of patients
studied to date [6-8,12,13]. A few earlier case series
showed that most patients with RB-ILD had a relatively
stable clinical course [12]. Subsequently, Portnoy et al’s
case series on the long-term outcomes of RB-ILD did not
support a benign course of RB-ILD, although prolonged
survival was still common [13]. Symptomatic and physio-
logic improvements were relatively rare, and neither
abstaining from cigarettes nor pharmacologic intervention
regularly led to clinically significant benefit. In turn, re-
gardless of smoking status, corticosteroids, or other ther-
apies, self-reported subjective deterioration in overall
status or of specific symptoms was commonly observed,
as were objective signs of clinical worsening determined
by spirometry and gas exchange measurements. Symp-
toms and physiology improved in only a minority of pa-
tients, although the study did agree that prolonged
survival could be expected in most patients with RB-ILD
and that mortality secondary to progressive ILD is rare.
Etiology and pathogenesis
RB-ILD corresponds to changes within pulmonary inter-
stitium that are known to occur almost exclusively in
current heavy cigarette smokers. However, the patho-
logic mechanisms that lead to these changes remain un-
clear, and RB-ILD is regarded as a manifestation of lung
parenchymal response to inhaled cigarette smoke in
both animals and humans [30,31]. The key feature ofthis manifestation is the bronchiolocentric accumulation
of yellow-brown pigmented macrophages and cellular or
fibrotic inflammation with associated clinical features of
ILD [6,8,14]. The pigment in these so called “smokers’
macrophages” represents cigarette smoke constituents,
most notably kaolinite (aluminum silicate) [32].
RB-ILD is commonly viewed as an amplified respira-
tory bronchiolitic response that, compared to the solely
bronchiole-centered lesions seen in RB, leads addition-
ally to interstitial and air space inflammation and fibrosis
extending to the nearby alveoli.
At the same time, RB-ILD has been distinguished from
the more exaggerated panlobular diffuse mild-to-moderate
interstitial fibrosis and massive accumulation of macro-
phages in the alveoli described in DIP [33]. Both of these
uncommon conditions have significant clinical and histo-
pathologic overlap [34] and were suggested to be syn-
onymous [7,11,35]. Together with a common pattern of
pathological abnormalities, RB-ILD and DIP show radio-
logical overlap. The only features that may differentiate
these two IIPs are the distribution and the extent of the le-
sions. This observation may again raise the question of
whether RB-ILD and DIP represent different points along
the spectrum of the same disease [1,9,36], although RB,
RB-ILD, and DIP representing various degrees of severity
of the same process caused by long-time tobacco smoking
is not commonly considered.
Because of the evidence of the etiological association
with cigarette smoking, the latest update of the ATS/ERS
classification of IIPs has grouped RB-ILD and DIP to-
gether within the major IIPs as smoking-related lung dis-
ease [10]. However, the pathogenic mechanism that links
tobacco-smoke exposure to these entities has not yet been
elucidated [37].
Although originally postulated by Niewoehner that RB
alone could be the precursor of centriacinar emphysema
[3], it remains largely unclear whether RB-ILD progresses
to emphysema, despite a few studies suggesting such a
possibility [38,39].
Diagnosis
It is increasingly accepted that a diagnosis of RB-ILD is se-
cure when based upon typical HRCT findings (ground-
glass opacities and centrilobular nodules) in a current
smoker, especially when bronchoalveolar lavage (BAL)
findings (the presence of smokers’ macrophages and the
absence of lymphocytosis) are also compatible. In case of
the assumption of an ILD other than RB-ILD, a surgical
biopsy may be necessary [1,10].
Diagnostic methods and criteria
Histologic features of surgical biopsy specimens
According to the international consensus classification
of the IIPs, the histopathologic diagnosis of RB-ILD
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phages within respiratory bronchioles and alveolar ducts,
associated with a patchy submucosal and peribronchiolar
chronic infiltrate of lymphocytes and histiocytes (Figure 1).
The common findings also include mild bronchiolar and
peribronchiolar alveolar fibrosis that stretches contiguous
alveolar septa and leads to architectural distortion as well
as centrilobular emphysema [1].Findings of bronchoalveolar lavage and
transbronchial biopsy
BAL findings in RB-ILD patients usually do not differ
from those seen in otherwise normal healthy smokers and
include an increased total number of cells with a normal
cellular differential analysis [13] or an increase in the per-
centage of macrophages [15]. These alveolar macrophages
contain brownish, golden, or black tobacco pigment inclu-
sions In the absence of these cells, an alternative diagnosis
should be considered. A modest increase in neutrophils
may also be present [40].
Transbronchial biopsy might be useful in distinguish-
ing RB-ILD from hypersensitivity pneumonitis (HP) or
sarcoidosis, but not from DIP. In one case, transbron-
chial biopsy was sufficient to establish a diagnosis of
acute RB-ILD [27].Figure 1 Photomicrograph (original magnification, x100;
hematoxylin-eosin stain) showing the characteristic histologic
features of RB-ILD. Pigmented macrophages in a terminal
bronchiole and the adjacent alveoli (arrows), and moderate
peribronchiolar inflammation and fibrosis (arrowhead) are present.
*Mueller-Mang C, Grosse C, Schmid K, et al.: What every radiologist
should know about idiopathic interstitial pneumonias. Radiographics
2007, 27:595–615. With permission from The Radiological Society of
North America.Radiographic findings
Radiographic findings are usually relatively subtle
[6,7,9,14]. Normal chest radiographs have been reported
in 20% to 28% of patients with histologically-proven RB-
ILD [6,7,41], and in a single case, both normal chest x-ray
and HRCT appearance were reported [41]. When present,
typical chest x-ray findings in patients with RB-ILD may
include fine reticulonodular interstitial opacities, which
are diffuse [7] or are predominant in basal lung areas [6].
The chest radiograph may also reveal signs of thickening
of the walls of the central and peripheral bronchi [6,7,9].
HRCT findings in RB-ILD patient are shown in Figure 2.
Some differences exist between studies in terms of fre-
quency of particular changes and their zonal predomin-
ance at HRCT. The most frequent findings reported by
Park et al. were central and peripheral bronchial wall
thickening (in 90% and 86% of patients, respectively) and
centrilobular nodules (71%) [14]. Ground-glass opacity
was observed significantly less frequently than in the earl-
ier series (67% vs. 100% of patients) [12]. Although in a
few other studies, the upper lung zones were mostly af-
fected [8,9,14], Park et al. did not report any zonal pre-
dominance. Centrilobular emphysema in the upper lobes
was reported consistently as a common (50%–57%) but not
severe finding [8,9,14]. Patchy areas of hypoattenuation
were less common (38%) and reported to have lower lung
predominance [14]. Most probably, this hypoattenuation
reflects air trapping due to small airway disease [14,42].
However, a tree-in-bud pattern, which is a common mani-
festation of small-airway-disease, was rarely reported [43].
The frequency of interstitial fibrosis in RB-ILD patients, as
determined by the presence of intralobular lines and aFigure 2 RB-ILD in a 44-year-old woman with a 20 pack-year
smoking history. HRCT image of the upper lung lobes shows
centrilobular nodules (white arrows), patchy ground-glass opacities
(black arrow), and mild coexisting centrilobular emphysema (arrowhead).
*Mueller-Mang C, Grosse C, Schmid K, et al.: What every radiologist
should know about idiopathic interstitial pneumonias. Radiographics
2007, 27:595–615. With permission from The Radiological Society of
North America.
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and ranged from 20% to 75% [8,9,13,41], while honeycomb-
ing was less common (0%–12%) [8,12,13].
Pulmonary function tests
Mixed, predominantly obstructive abnormalities, often
combined with hyperinflation and usually associated
with a mild to moderate reduction in DLco are the most
frequently reported findings in patients diagnosed with
RB-ILD [6-8,13]. Airflow obstruction is usually mild.
Differential diagnosis
First, the entities that share a common pathogenesis and
clinical-histopathological pattern with RB-ILD, i.e., RB
and DIP, should be taken into account in the differential
diagnosis. However, separating RB and RB-ILD by sole
histopathological criteria remains controversial; more-
over, the two entities can also rarely be distinguished
solely by the nature and extent of HRCT findings, be-
cause there is no arbitrary cut-off point for which the
extent of disease at HRCT evolves from RB to RB-ILD
[5-9]. Therefore, it has been proposed that the distinc-
tion between RB and RB-ILD should be based not on
histological or radiological appearance alone, but on all
markers of disease severity taken together, including
clinical symptoms, pulmonary function tests results, and
HRCT findings. On the contrary, lung biopsy is some-
times required to distinguish RB-ILD from DIP. Al-
though RB-ILD can usually be distinguished from DIP
radiologically with HRCT, there is considerable overlap
between these two IIPs. In the face of the different prog-
noses associated with these entities [7], correct diagnosis
is of considerable importance. For the pathologist, a
challenge in the differential diagnosis might be the
separation of the fibrotic form of RB-ILD that was
suggested by Yousem from DIP [44]. This histologic ap-
pearance has been linked to a macrophage-poor variant of
DIP, and the term RB-ILD with fibrosis has been suggested
to represent a subset of diagnoses at the extreme end of
the RB-ILD spectrum [44]. Further, both RB-ILD and DIP
need to be differentiated from airspace enlargement with
fibrosis (AEF), the changes which have been inciden-
tally reported on histologic and HRCT examination in
smokers, and in comparison to emphysema marked by
more extensive interstitial fibrosis [45,46]. In addition, the
histopathological distinction between RB-ILD and centri-
lobular emphysema, which is usually associated with RB
and sometimes with interstitial fibrosis, appears to be an-
other challenge. It has been postulated that functional ab-
normalities might help in making a definite diagnosis [47].
Next, other ILDs, including nonspecific interstitial
pneumonia (NSIP) and subacute HP, should be taken
into account in differential diagnosis. Usually these can
be effectively excluded based on the HRCT findings: theground-glass opacity observed in RB-ILD is usually
patchier than that seen in NSIP or acute or subacute
HP; additionally, a greater extent of micronodules in
acute or subacute HP and the presence of diffuse bron-
chial wall thickening in RB-ILD may help in differentiat-
ing the two entities [14]. Additionally, a history of
smoking (rare in HP) together with BAL findings (lym-
phocytosis in HP) can assist in differentiating RB-ILD
from subacute HP [14,15,48].
Management and disease course
The indications for treatment of RB-ILD are often mar-
ginal. Although to date, the regression of findings consist-
ent with RB-ILD after discontinuation of smoking not
accompanied by corticosteroid therapy has been reported
in few patients [6,15,49], smoking cessation is considered
the most important factor in the management of RB-ILD.
Because the majority of patients in reported case series re-
ceived corticosteroid and/or immunosuppressive therapy
along with smoking cessation, it is not yet completely
understood whether smoking cessation alone can improve
outcomes in RB-ILD [7,8,12,14,49]. It is also unclear
whether patients with RB-ILD benefit from corticosteroid
therapy with regard to the natural history of the disease.
In one report, at follow-up HRCT after corticosteroid
treatment and smoking cessation, the extent of bronchial
wall thickening, centrilobular nodules, and ground-glass
opacities had decreased in 43% of patients, while areas of
hypoattenuation had increased as emphysema was irre-
versible on follow up [14]. However, other studies have
presented cases with no change or deterioration despite
corticosteroid therapy [8,12], or the failure of corticoster-
oid tapering and discontinuation even in the absence of
smoking [12].
So far, the prognosis for patients with RB-ILD has been
good, with prolonged survival expected in most cases.
Until now only one death from progressive lung disease
during a median follow-up period of 7 years has been re-
ported during a study that explored the outcomes in 32
RB-ILD patients [13]. However, in the absence of other
longitudinal data, the median survival time can be only
approximate. As was suggested in the study just men-
tioned, at least 75% of the patients would be expected to
live at least 7 years [13], although this case series with long
follow-up did not support the contention that RB-ILD is a
benign disease. Clinical worsening was common, as well
as worsening of spirometry results and gas exchange, re-
gardless of smoking status and treatment ordered, includ-
ing corticosteroids [13].
To summarize, the course of RB-ILD is heterogeneous,
often with no functional improvement and with disease
progression despite smoking cessation and treatment
[8,12,13]. In contrast to previous assumptions, RB-ILD is
now less commonly regarded as a benign entity.
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1. What are the incidence and prevalence of the
RB-ILD?
2. What is the relationship of RB-ILD to other forms
of IIPs?
3. What is the relationship of RB-ILD to DIP, and does
RB-ILD progress to DIP?
4. What are the potential causes of RB-ILD other than
cigarette smoking?
5. Does RB-ILD advance to emphysema?
6. Do smoking cessation and treatment with
corticosteroids alter the natural history of RB-ILD?
7. Do any HRCT features of RB-ILD improve following
smoking cessation?
Conclusions
RB-ILD is a rare and not fully understood disease. This
clinicopathologic syndrome combines RB and ILD. Be-
cause of the evidence of the etiological association with
cigarette smoking, RB-ILD is referred to as smoking-
related ILD. However, the pathogenic mechanism that
links tobacco-smoke exposure to this entity has not yet
been clarified, and thus it is still regarded as idiopathic dis-
ease. RB-ILD has significant pathological/clinical/radio-
logical overlap with DIP, what raises the question whether
RB-ILD and DIP represent different points along the
spectrum of the same disease. Further clarification of the
relationship between RB-ILD and DIP is warranted. The
exact prevalence and incidence of RB-ILD is unknown.
Similarly, long-term outcome of RB-ILD awaits recognition.
The condition seems not to be as benign as it was previ-
ously considered. Some patients respond favorably to corti-
costeroids and/or smoking cessation, but often the disease
progresses despite smoking cessation and treatment. It also
remains unclear whether RB-ILD progresses to emphysema.
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